ISM2 and colorectal carcinoma: Six biomarkers (HOTAIR, ISM2, KRTAP3-1, SPDYC, LY6G6F, and NKD1) found no drug available in LINCS1000 (Subramanian et al., 2017) to modulate their expression, and these constitute potential novel targets for drug discovery against metastatic transition in CRC.